RWJ 51521
Latest Information Update: 25 Jun 2003
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 07 May 2001 New profile
- 07 May 2001 Preclinical development for Anxiety disorders in USA (Unknown route)